Search results (25)
« Back to NewsWorld's first Phase II Nipah virus vaccine trial launch
9 December 2025
The University of Oxford has launched the world’s first Phase II clinical trial of a Nipah virus vaccine candidate.
First volunteer receives Lassa Fever vaccine in cutting-edge Oxford trial
8 December 2025
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus.
World’s first lung cancer prevention vaccine gets £2 million for clinical trial
17 November 2025
People at high risk of lung cancer will soon be able to receive the first-ever experimental vaccine, 'LungVax', designed to prevent the disease, in a world-first clinical trial. The LungVax vaccine carries a series of genetic instructions which train the immune system to recognise tumour antigens on the surface of abnormal lung cells.
The GEKO trial launches to bridge the gap in knee osteoarthritis care
30 October 2025
A new multicentre trial to evaluate a minimally invasive treatment for patients with knee osteoarthritis could transform the way knee osteoarthritis is managed, potentially improving quality of life for patients long before surgery becomes necessary.
First volunteers receive Rift Valley fever vaccine in Kenya Phase II trial
15 August 2025
On 8 July 2025, researchers at the KEMRI-Wellcome Trust Research Programme began the Phase II trial of the ChAdOx1 RVF vaccine in Kilifi, Kenya—the most advanced Rift Valley fever vaccine study in an outbreak-prone region. Led by Oxford University and funded by CEPI, this milestone brings us closer to a licensed vaccine for protecting lives and livelihoods.
Celebrating innovation: the PRINCIPLE-PANORAMIC Celebratory Symposium and art exhibition
17 April 2024
Researchers, clinicians, supporters and PPI contributors gathered at the symposium to celebrate the innovative PRINCIPLE and PANORAMIC clinical trials that evaluated potential treatments for COVID-19 during the pandemic and broke recruitment records for community-based trials in doing so. Both trials were run by the Clinical Trails Unit (CTU) in Nuffield Department of Primary Care Health Sciences.
Celebrating collaboration and resilience: The PRINCIPLE PANORAMIC art exhibition
21 March 2024
Celebrate the resilience and collaboration behind Oxford's groundbreaking PANORAMIC and PRINCIPLE COVID-19 trials through "The PANORAMIC PRINCIPLE" exhibition. Artist Tanya Poole's powerful portraits honour the diverse array of participants, researchers, and medical professionals whose inclusive efforts set global benchmarks and transformed lives. An inspiring tribute to human determination in the face of adversity.
New phase 3 trial data confirm the uniquely high efficacy and good safety profile of the R21/Matrix-M malaria vaccine in African children
1 February 2024
Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5–17-month age group over the first year To date 25 million doses manufactured and ready for roll-out by The Serum Institute of India (SII) in the next three to four months
Nuffield Department of Primary Care Health Sciences set to deliver clinical trials expertise to China National Biotec Group in new collaboration
28 November 2023
The training initiative builds the foundations to explore further collaborations encompassing joint research efforts, leadership programmes, and a shared commitment to advancing clinical trials.
Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines
26 October 2023
This study will test the responses of cells in lymph nodes before and after immunisation with flu and COVID-19 vaccines and compare reactions in older and younger adults
Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out
2 October 2023
The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant is critical to reducing over half a million malaria-related deaths annually.
Oxford and Liverpool scientists launch new vaccine trial for Middle East Respiratory Syndrome (MERS)
19 September 2023
The UK trial is the next step in the development of a vaccine to protect people against MERS – a deadly viral illness with no current vaccines and the potential to cause a pandemic.
First volunteers receive vaccine for Crimean-Congo haemorrhagic fever in Oxford clinical trial
13 September 2023
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
Oxford to launch UK’s first trials unit dedicated to precision-prevention and early detection studies
18 July 2023
Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
African Phase I HIV vaccine trial shows encouraging preliminary results
12 July 2023
The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully.
Drug shows promise for stroke patients with bleeding in brain
4 July 2023
A clinical trial has shown that a drug commonly used for patients with bleeding disorders has the potential to be used to lessen the side effects of blood-thinning drugs for patients who have experienced a stroke.
Rapid weight loss found to be safe and helpful for people with liver disease, Oxford trial reveals
28 June 2023
A clinical trial, led by a team at NDPCHS, has shown that a three-month rapid weight loss programme was not only safe but also effective in reducing the severity of a liver disease called non-alcoholic steatohepatitis (NASH) with liver fibrosis.
Major trials to test effectiveness of cannabidiol on psychosis
16 February 2023
A global study involving three clinical trials will investigate the effectiveness of cannabidiol (CBD) in treating people with psychosis or psychotic symptoms, thanks to a multi-million pound grant to Oxford University.
Oxford spinout trials revolutionary bioelectronic implant to treat incontinence
1 February 2023
The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.
Molnupiravir doesn't reduce COVID-19 hospitalisations in high-risk vaccinated people
3 January 2023
Researchers from the University of Oxford released findings from a clinical trial investigating the effectiveness of the antiviral treatment molnupiravir against COVID-19 – the first treatment tested in the ongoing PANORAMIC trial. In their paper published in The Lancet, they reported that molnupiravir did not reduce hospitalisations or deaths among higher risk, vaccinated adults with COVID-19 in the community.